Zymeworks
ZYME
26.53
+0.88
+3.43%
Zymeworks
US · ZYME
#2828 by market cap
Listed 2017
26.53
+0.88
+3.43%
Live - 5344 symbols - heartbeat 441s ago
· 2026-10-08 05:35
Pre-market
26.48
-0.19%
After-hours
25.99
-2.04%
- Market cap
- 1.90B
- P/E (TTM)i
- -13.13
- P/Bi
- 23.69
- EPSi
- -1.08
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on ZYME?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.93, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +38.87% YoY
Margins
- Operating margin
- -87.33%
- Net margin
- -76.56%
Key ratios & quality
- Altman Z-Scorei
- 10.93
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 53.02M | 29.54M | 38.95M | 26.68M | 412.48M | 76.01M | 76.30M | 105.97M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 29.46M | 62.70M | 55.20M | 42.60M | 73.40M | 70.40M | 61.50M | 61.50M |
| Research & development | 56.93M | 117.37M | 171.20M | 199.75M | 208.60M | 143.62M | 134.62M | 137.00M |
| Operating profit | -33.36M | -150.52M | -187.45M | -215.67M | 130.49M | -138.01M | -119.82M | -92.54M |
| Pretax profit | -34.39M | -146.02M | -180.12M | -212.36M | 135.23M | -119.24M | -116.61M | -79.75M |
| Tax | 2.17M | -582.00K | 429.00K | -516.00K | 10.89M | -568.00K | 6.08M | 1.38M |
| Net profit | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.70M | -81.13M |
| Basic EPS | -1 | -4 | -4 | -4 | 2 | -2 | -2 | -1 |
| Diluted EPS | -1.26 | -3.83 | -3.58 | -4.61 | 1.90 | -1.72 | -1.62 | -1.08 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 27.11M | 48.73M | 27.61M | 2.52M | 2.41M | 4.59M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 17.00M | 14.90M | 14.10M | 15.40M | 15.10M | 19.30M |
| Research & development | 35.74M | 34.45M | 35.58M | 31.24M | 34.46M | 27.44M |
| Operating profit | -25.63M | -623.00K | -22.06M | -44.12M | -47.15M | -42.15M |
| Pretax profit | -22.14M | 2.13M | -18.27M | -41.48M | -46.35M | -45.29M |
| Tax | 496.00K | -186.00K | 1.34M | -270.00K | -2.19M | -273.00K |
| Net profit | -22.64M | 2.32M | -19.60M | -41.21M | -44.16M | -45.02M |
| Basic EPS | 0 | 0 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.30 | 0.03 | -0.26 | -0.55 | -0.59 | -0.62 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 204.37M | 311.83M | 455.08M | 288.22M | 544.71M | 412.93M | 300.45M | 248.77M |
| Cash & ST investments | 200.16M | 298.90M | 426.35M | 252.61M | 492.23M | 374.33M | 225.78M | 228.80M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 244.48M | 368.21M | 538.38M | 389.13M | 648.73M | 580.88M | 463.09M | 346.53M |
| Total current liabilities | 29.99M | 82.55M | 85.67M | 71.85M | 95.63M | 55.76M | 88.29M | 42.32M |
| Short-term debt | -- | 1.28M | 2.71M | 1.31M | 3.32M | 4.26M | 2.74M | 3.47M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 63,987,000.00 | 122,524,000.00 | 128,454,000.00 | 140,038,000.00 | 155,769,000.00 | 116,074,000.00 | 124,323,000.00 | 78,026,000.00 |
| Total equity | 180.49M | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M | 338.77M | 268.50M |
| Retained earnings | -145.27M | -290.71M | -471.26M | -683.10M | -558.76M | -677.44M | -830.34M | -953.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 306.47M | 296.13M | 291.71M | 248.77M | 385.68M | 298.39M |
| Cash & ST investments | 265.29M | 281.38M | 251.93M | 228.80M | 364.73M | 270.70M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 425.52M | 408.39M | 397.27M | 346.53M | 478.22M | 396.96M |
| Total current liabilities | 65.10M | 38.50M | 42.04M | 42.32M | 35.65M | 47.24M |
| Short-term debt | 3.26M | 3.59M | 3.40M | 3.47M | 3.28M | 3.30M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 100,555,000.00 | 73,879,000.00 | 77,205,000.00 | 78,026,000.00 | 314,626,000.00 | 316,595,000.00 |
| Total equity | 324.97M | 334.51M | 320.06M | 268.50M | 163.59M | 80.37M |
| Retained earnings | -852.97M | -850.65M | -886.47M | -953.16M | -1.07B | -1.17B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 24.18M | -81.85M | -151.40M | -192.45M | 144.11M | -118.32M | -110.06M | -33.01M |
| Depreciation & amortization | 3.63M | 7.33M | 10.28M | 9.58M | 12.00M | 17.31M | 11.19M | 11.11M |
| Free cash flow | 20.76M | -95.73M | -157.67M | -205.74M | 130.98M | -122.40M | -113.12M | -35.36M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 90.75M | 188.23M | 300.91M | 0 | 107.53M | 76.10M | -30.05M | -36.71M |
| Ending cash balance | 42.21M | 128.45M | 242.04M | 201.87M | 400.91M | 157.56M | 66.10M | 41.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -3.41M | 12.07M | -31.41M | -10.26M | -45.72M | -31.95M |
| Depreciation & amortization | 3.31M | 3.21M | 2.58M | 2.01M | 2.85M | 1.95M |
| Free cash flow | -3.75M | 11.19M | -31.82M | -10.98M | -45.93M | -31.95M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -11.23M | -25.48M | 173.85M | -51.95M |
| Ending cash balance | 76.20M | 98.25M | 64.83M | 41.16M | 244.28M | 179.41M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -24.62 | -68.25 | -55.08 | -64.29 | 33.45 | -24.78 | -30.54 | -26.72 |
| ROA %i | -19.43 | -47.48 | -39.83 | -45.68 | 23.92 | -19.30 | -23.51 | -20.04 |
| ROIC %i | -25.84 | -69.92 | -55.04 | -61.09 | 30.11 | -27.31 | -32.40 | -28.28 |
| 5-year avg ROE %i | -- | -92.72 | -82.72 | -45.93 | -35.75 | -35.78 | -28.24 | -22.56 |
| EBIT margin %i | -64.54 | -509.52 | -481.29 | -808.37 | 31.63 | -181.56 | -157.03 | -87.33 |
| FCF / sales %i | 39.15 | -- | -- | -- | 31.76 | -- | -- | -- |
| Current ratioi | 6.82 | 3.78 | 5.31 | 4.01 | 5.70 | 7.41 | 3.40 | 5.88 |
| Quick ratioi | 6.69 | 3.65 | 5.16 | 3.73 | 5.50 | 7.06 | 3.19 | 5.52 |
| Debt / assetsi | 0.02 | 1.88 | 1.61 | 8.31 | 4.33 | 4.60 | 4.00 | 5.27 |
| LT debt / equityi | 0.02 | 2.30 | 1.45 | 12.45 | 5.03 | 4.83 | 4.65 | 5.51 |
| Interest coveragei | -206.14 | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 76.39 | 38.97 | -9.04 | -20.46 | 140.79 | 24.96 | 41.95 | -36.43 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -29.80 | -19.89 | -18.46 | -26.72 | -42.02 | -72.31 |
| ROA %i | -23.22 | -15.95 | -14.34 | -20.04 | -22.72 | -37.25 |
| ROIC %i | -31.40 | -21.91 | -20.43 | -28.28 | -43.94 | -72.24 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -115.26 | -67.26 | -52.53 | -87.33 | -141.12 | -418.86 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.71 | 7.69 | 6.94 | 5.88 | 10.82 | 6.32 |
| Quick ratioi | 4.45 | 7.38 | 6.69 | 5.52 | 10.36 | 5.86 |
| Debt / assetsi | 4.34 | 4.57 | 4.76 | 5.27 | 3.56 | 4.03 |
| LT debt / equityi | 4.68 | 4.51 | 4.84 | 5.51 | 8.41 | 15.81 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Biotherapeutics segment100.00%
Quote time 2026-10-08 05:35:07 · For reference only, not investment advice and not tailored to your situation.